Dicerna Pharmaceuticals Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Dicerna |
Dicerna Pharmaceuticals Company Z Score Analysis
Dicerna Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Dicerna Pharmaceuticals Z Score | 16.1 |
Most of Dicerna Pharmaceuticals' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dicerna Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionAccording to the company's disclosures, Dicerna Pharmaceuticals has a Z Score of 16.1. This is 138.52% higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is 84.63% lower than that of the firm.
Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
All Next | Launch Module |
Dicerna Fundamentals
Return On Equity | -95.22 | |||
Return On Asset | -10.43 | |||
Profit Margin | (64.53) % | |||
Operating Margin | (62.88) % | |||
Current Valuation | 2.48 B | |||
Shares Outstanding | 77.91 M | |||
Shares Owned By Insiders | 7.43 % | |||
Shares Owned By Institutions | 88.54 % | |||
Number Of Shares Shorted | 4.77 M | |||
Price To Earning | (1.58) X | |||
Price To Book | 27.64 X | |||
Price To Sales | 15.44 X | |||
Revenue | 192.85 M | |||
Gross Profit | (41.08 M) | |||
EBITDA | (116.73 M) | |||
Net Income | (124.44 M) | |||
Cash And Equivalents | 565.51 M | |||
Cash Per Share | 7.26 X | |||
Total Debt | 64.42 M | |||
Debt To Equity | 0.60 % | |||
Current Ratio | 2.46 X | |||
Book Value Per Share | 1.38 X | |||
Cash Flow From Operations | 21.05 M | |||
Short Ratio | 0.84 X | |||
Earnings Per Share | (1.63) X | |||
Number Of Employees | 302 | |||
Beta | 0.79 | |||
Market Capitalization | 2.98 B | |||
Total Asset | 62.95 M | |||
Retained Earnings | (539.14 M) | |||
Working Capital | 49.56 M | |||
Current Asset | 59.38 M | |||
Current Liabilities | 9.82 M | |||
Z Score | 16.1 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |